Galectin Therapeutics Inc...

NASDAQ: GALT · Real-Time Price · USD
3.57
-0.19 (-5.05%)
At close: Aug 15, 2025, 3:59 PM
3.55
-0.56%
After-hours: Aug 15, 2025, 06:50 PM EDT

Galectin Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
37K 33K 32K 41K
Gross Profit
n/a -33K -32K -41K
Operating Income
-42.43M -38.07M -38.35M -30.18M
Interest Income
338K 230K 52K 3K
Pretax Income
-47.05M -41.07M -38.78M -30.53M
Net Income
-47.05M -41.07M -38.78M -30.53M
Selling & General & Admin
5.86M 5.94M 6.62M 6.36M
Research & Development
36.57M 32.13M 31.74M 23.82M
Other Expenses
n/a -0.00 n/a n/a
Operating Expenses
42.43M 38.04M 38.35M 30.18M
Interest Expense
5.54M 2.79M 1.03M 489K
Selling & Marketing Expenses
n/a 44K n/a n/a
Cost & Expenses
n/a 38.07M 38.35M 30.18M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
62.31M 60.16M 59.39M 58.53M
Shares Outstanding (Diluted)
62.31M 60.16M 59.39M 58.53M
EPS (Basic)
-0.76 -0.74 -0.65 -0.52
EPS (Diluted)
-0.76 -0.74 -0.65 -0.52
EBITDA
-41.47M -38.24M -38.27M -30M
EBIT
-41.51M -38.27M -37.74M -30.18M
Depreciation & Amortization
37K 33K 32K 41K